Cullinan Oncology is a biopharmaceutical company focused on developing innovative therapeutics to redefine treatment standards for cancer and autoimmune diseases. We leverage a diverse portfolio of clinical-stage assets that strategically target disease mechanisms and utilize cutting-edge modalities. Our deep expertise in oncology and immunology drives us to rapidly advance the most promising therapeutic candidates from idea to clinic.
